Type
| |
Name |
|
Progress |
|
Estimated Release |
|
|
|
|
|
|
|
Treatment |
|
Actemra (tocilizumab), interleukin-6 receptor antagonist |
|
|
|
Apr-20 |
Treatment |
|
Gimsilumab, antigranulocyte-macrophage colony stimulating factor monoclonal |
|
|
|
Apr-20 |
Treatment |
|
Sylvant (siltuximab), interleukin-6 targeted monoclonal |
|
|
|
Apr-20 |
Treatment |
|
LY3127804, antiAngiopoietin 2 (Ang2) antibody |
|
|
|
Apr-20 |
Treatment |
|
Favilavir/Favipiravir/T-705/ Avigan, licensed in Japan to treat influenza |
|
|
|
Apr-20 |
Treatment |
|
galidesivir |
|
|
|
Apr-20 |
Treatment |
|
EIDD-2801, oral ribonucleoside analog |
|
|
|
Apr-20 |
Treatment |
|
CYNK-001, allogeneic, natural killer cell therapy |
|
|
|
Apr-20 |
Treatment |
|
Peginterferon lambda |
|
|
|
Apr-20 |
Treatment |
|
APN01; recombinant soluble human Angiotensin Converting Enzyme 2 |
|
|
|
Apr-20 |
Treatment |
|
nafamostat, approved in Japan to treat pancreatitis and other diseases |
|
|
|
Apr-20 |
Treatment |
|
ARMS-1 |
|
|
|
Apr-20 |
Treatment |
|
CD24Fc, biological immunomodulator |
|
|
|
Apr-20 |
Treatment |
|
Aviptadil, synthetic form of Vasoactive Intestinal Polypeptide |
|
|
|
Apr-20 |
Treatment |
|
vazegepant, CGRP receptor antagonist |
|
|
|
Apr-20 |
Treatment |
|
CM4620-IE, calcium releaseactivated calcium (CRAC) channel inhibtor |
|
|
|
Apr-20 |
Treatment |
|
CytoSorb (blood purification device, extracorporeal cytokine adsorber) |
|
|
|
Apr-20 |
Treatment |
|
Extracorporeal blood purification (EBP) devices |
|
|
|
Apr-20 |
Vaccine |
|
DNA (vaccine) |
|
|
|
Apr-20 |
Vaccine |
|
Inactivated (formaldehydeinactivated + alum) (vaccine) |
|
|
|
Apr-20 |
Vaccine |
|
Non-replicating viral vector; ChAdOx1 (vaccine) |
|
|
|
Apr-20 |
Vaccine |
|
Non-replicating viral vector; Adenovirus Type 5 vector (Ad5- nCoV) |
|
|
|
Apr-20 |
Vaccine |
|
Protein subunit, adjuvanted microsphere peptide |
|
|
|
Apr-20 |
Vaccine |
|
Replicating viral vector; measles vector |
|
|
|
Apr-20 |
Vaccine |
|
RNA; BNT162 |
|
|
|
Apr-20 |
Vaccine |
|
RNA; liposome-encapsulated mRNA |
|
|
|
Apr-20 |
Treatment |
|
PD-1 blocking antibody; Thymosin |
|
|
|
May 2020 |
Treatment |
|
Methylprednisolone / ciclesonide/ hydrocortisone/ corticosteroids |
|
|
|
May 2020 |
Treatment |
|
remdesivir, nucleotide analog |
|
|
|
May 2020 |
Treatment |
|
ASC09, HIV protease inhibitor |
|
|
|
May 2020 |
Treatment |
|
Artifical intellegencebased screening to identify repurposed drug combinations |
|
|
|
May 2020 |
Treatment |
|
LAU-7b (fenretinide) |
|
|
|
May 2020 |
Vaccine |
|
NVX-CoV2373; Protein subunit; Full length S trimers/nanoparticle + Matrix M |
|
|
|
May 2020 |
Vaccine |
|
PittCoVacc, Protein subunit, microneedle arrays S1 subunit |
|
|
|
June 2020 |
Vaccine |
|
Protein subunit; S protein |
|
|
|
June 2020 |
Vaccine |
|
RNA; LNP-encapsulated mRNA (mRNA 1273 |
|
|
|
June 2020 |
Vaccine |
|
RNA; mRNA |
|
|
|
June 2020 |
Treatment |
|
Antibodies targeting the S protein from convalescent serum, humanized mice |
|
|
|
June 2020 |
Treatment |
|
Antibody |
|
|
|
June 2020 |
Treatment |
|
SAB-185, Polyclonal hyperimmune globulin (H-IG) |
|
|
|
June 2020 |
Treatment |
|
Chloroquine/ Hydroxychloroquine, antimalarial |
|
|
|
June 2020 |
Vaccine |
|
Deoptimized live attenuated virus |
|
|
|
June 2020 |
Vaccine |
|
DPX-COVID-19, protein subunit, lipid-based delivery platform |
|
|
|
June 2020 |
Vaccine |
|
LUNAR-COV19; RNA; mRNA |
|
|
|
June 2020 |
Vaccine |
|
RNA; saRNA |
|
|
|
June 2020 |
Treatment |
|
Antibodies from mice, REGN3048-3051, against the spike protein |
|
|
|
June 2020 |
Treatment |
|
Antibodies from recovered COVID-19 patients (1) |
|
|
|
July 2020 |
Treatment |
|
Antibodies from recovered COVID-19 patients (2) |
|
|
|
July 2020 |
Treatment |
|
Gilenya (fingolimod), sphingosine 1-phosphate receptor modulator |
|
|
|
July 2020 |
Treatment |
|
Antibodies from recovered COVID-19 patients (3) |
|
|
|
August 2020 |
Treatment |
|
Polyclonal hyperimmune globulin (H-IG) |
|
|
|
August 2020 |
Treatment |
|
Horse plasma product (COVID-EIG) |
|
|
|
August 2020 |
Treatment |
|
Prezcobix (darunavir, HIV-1 protease inhibitor/cobicistat, CYP3A inhibitor) |
|
|
|
August 2020 |
Vaccine |
|
CoroFlu, self-limiting influenza virus |
|
|
|
September 2020 |
Vaccine |
|
Unknown (SK Biosciences) |
|
|
|
September 2020 |
Vaccine |
|
Non-replicating viral vector; Ad26 (alone or with MVA boost) |
|
|
|
September 2020 |
Vaccine |
|
Self-assembling vaccine (fusion protein of a heat shock protein and Avidin) |
|
|
|
October 2020 |